Glioblastoma is the most aggressive of glial tumours in adults. On conventional magnetic
resonance (MR) imaging, these tumours are observed as irregular enhancing lesions with …

Simple Summary In this review, we discuss the role of isocitrate dehydrogenase in a normal
biological context and its subsequent role in oncogenesis when certain mutations are …

OBJECTIVE IDH-mutant diffuse low-grade gliomas (dLGGs; WHO grade 2) are often
considered to have a more indolent course. In particular, in patients with 1p19q codeleted …

The introduction of molecular criteria into the classification of diffuse gliomas has added
interesting practical implications to glioma management. This has created a new clinical …

Isocitrate dehydrogenase (IDH) mutation status is an important biomarker in the glioma-
defining subtype and corresponding prognosis. This study proposes a straightforward …

Objective. To evaluate the diagnostic value of multimodal MRI radiomics based on T2‐
weighted fluid attenuated inversion recovery imaging (T2WI‐FLAIR) combined with T1 …

Background The role of isocitrate dehydrogenase (IDH) mutation status for glioma
stratification and prognosis is established. While structural magnetic resonance image (MRI) …

The clinical efficacy of isocitrate dehydrogenase (IDH) inhibitors in the treatment of patients
with grade 2 IDH-mutant (mIDH) gliomas is a significant therapeutic advancement in neuro …

Introduction Outcomes for patients with high grade gliomas have changed little over the past
thirty years. This realization prompted renewed efforts to increase flexibility in the design and …

Purpose Currently, there remains a scarcity of established preoperative tests to accurately
predict the isocitrate dehydrogenase (IDH) mutation status in clinical scenarios, with limited …